At the beginning of this year, the construction of a New Medicine Research Institute has been formally initiated in Taizhou, which indicates the transformation of the Yangtze River Pharmaceutical Group (hereinafter referred to as YRPG)  into an enterprise that leans great efforts on science and technology innovation. This high-tech research platform, with an investment of RMB 1,800 million Yuan, is established in cooperation with the scientific research resources at home and abroad, and has received a support of RMB 30 million Yuan as a special fund from Jiangsu Provincial Science and Technology Department.

With many years of experience in operation, YRPG has deeply realized that the decisive factor for an enterprise to win in innovation is to build a supporting platform for innovative talents.

YRPG combines its brand and property advantages with the human and technology resources in universities as well as in science and technology research institutes and makes the best use of them. YRPG has invited many academicians as its research and development advisers by means of joint research projects. It has also established a long-term and stable production, teaching, and research cooperation program with dozens of universities and research institutes, such as China Pharmaceutical University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shenyang Pharmaceutical University, and nearly 100 joints program have been finished. There is a research and development team consists of more than 100 talents at the Medicine Research Institute in the headquarters in Taizhou, which ensures the production of over 10 types of new medicines every year.

YRPG will never stop investing in technology. Its total investment in science and technology has surpassed 2,000 million Yuan in the last ten years. During the Tenth Five-year Plan period, YRPG has put 5% of its sales income into science and technology innovation annually. After each technology innovation, the enterprise will undergo a thorough change, and it has been changed from a small factory into a large enterprise with two main plant areas in the south and north respectively as well as 5 modernized subsidiaries.  

The construction of an advanced research and development platform by joint force is one of the bright spots of the enterprise’s strategy. In 2004, the Sino-US Sijia Medicine Research Institute was founded in Shanghai, focusing on the synthesis and screening of novel compounds. In recent 3 years, more than 1,000 kinds of novel compounds have been synthesized for medicine screening.

         Concerning the research and development of chemical medicine, YRPG has explored a new development road of importation-digestion-absorption-renovation. At present, the enterprise produces chemical medicines of various kinds, including ten types of drugs, such as antimicrobial, antineoplastic, and cardio- cerebral system, etc. 

 In recent years, YRPG has spent nearly a hundred million Yuan on the research and development of new drugs. Aiming at the frontiers of science and technology of medicine, the enterprise selected 42 different kinds of drugs as its research targets, 4 of which are first grade new medicines.